文献速递消化道肿瘤与早癌食管胃疾病与幽门螺杆菌

PDE5A+癌相关成纤维细胞增强胃癌免疫抑制

PDE5A+ cancer-associated fibroblasts enhance immune suppression in gastric cancer.
PubMed 文献 · Gut · 2025-10-20

该研究对24例胃癌患者行单细胞RNA测序,并对患者及对照的FFPE组织切片行空间转录组分析,结合体内外实验,发现PDE5A+癌相关成纤维细胞通过PI3K/AKT/mTOR通路释放CXCL12招募CD8+ TEX+ LAG3 T细胞,促进免疫抑制微环境;LAG3阻断联合PDE5A抑制剂伐地那非可增强小鼠模型免疫治疗反应。

要点

  • PDE5A+ CAFs与胃癌患者总生存期缩短及免疫抑制微环境形成相关。
  • PDE5A+ CAFs通过PI3K/AKT/mTOR通路释放CXCL12招募CD8+ TEX+ LAG3 T细胞。
  • LAG3阻断联合PDE5A抑制剂伐地那非可增强小鼠模型免疫治疗反应。

核心结论

  • PDE5A+ CAFs在胃癌免疫抑制微环境塑造中起关键作用,为胃癌治疗提供机制见解和潜在治疗策略。

研究设计与样本

  • 对24例胃癌患者行单细胞RNA测序,并对患者及对照的FFPE组织切片行空间转录组分析。
  • 结合体内外研究进一步阐明分子机制。

主要发现

  • PDE5A表达与胃癌患者较短总生存期和免疫抑制微环境形成相关。
  • PDE5A+ CAFs与T细胞排斥及CD8+细胞毒性T淋巴细胞浸润减少相关。
  • PDE5A+ CAFs通过重塑细胞外基质促进胃癌细胞上皮-间质转化。
  • PDE5A+ CAFs通过触发PI3K/AKT/mTOR信号通路释放CXCL12,结合CXCR4受体招募CD8+ TEX+ LAG3 T细胞。
  • LAG3阻断联合PDE5A抑制剂伐地那非有效增强小鼠模型免疫治疗反应并显著抑制胃癌进展。

临床怎么用

  • PDE5A+ CAFs可作为胃癌免疫抑制微环境的潜在标志,LAG3阻断联合PDE5A抑制剂伐地那非可能增强免疫检查点抑制剂疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Gastric cancer (GC) ranks among the most prevalent lethal tumours globally. Cancer-associated fibroblasts (CAFs) are pivotal in creating an immunosuppressive tumour microenvironment (TME) in GC. OBJECTIVE: Identifying a critical subpopulation of CAFs in promoting an immunosuppressive TME and enabling immune evasion, which may influence therapeutic effectiveness of immune checkpoint inhibitors (ICIs) for GC. DESIGN: We performed single-cell RNA sequencing on 24 patients with GC and spatial transcriptomic profiling on formalin-fixed paraffin-embedded tissue sections from patients and controls. Integrating these data, we mapped cell types and gene signatures and identified distinct CAF subpopulations in the TME that influenced immunotherapy response in patients with GC. In vitro and in vivo studies further elucidated the molecular mechanisms, enhancing therapeutic implications. RESULTS: In patients with GC, phosphodiesterase type 5A (PDE5A) expression was associated with shorter overall survival and the formation of immunosuppressive TME. We identified PDE5A+ CAFs that were associated with TME alterations, including T cell exclusion and reduced CD8+ cytotoxic T lymphocyte infiltration, potentially impairing the efficacy of immunotherapy in GC. PDE5A+ CAFs were observed to promote the epithelial-mesenchymal transition of GC cells through remodelling extracellular matrix. Furthermore, PDE5A+ CAFs, via triggering of the PI3K/AKT/mTOR signalling pathway, released CXCL12, which engaged the CXCR4 receptor, consequently recruiting CD8+ TEX+ LAG3 T cells to facilitate the development of immunosuppressive TME. The combined treatment of LAG3 blockade and PDE5A inhibitor vardenafil effectively enhanced immunotherapy responses, significantly curbing GC progression in mouse models. CONCLUSIONS: Our study elucidates the intricate role of PDE5A+ CAFs in shaping the immunosuppressive TME in GC, providing mechanistic insights and therapeutic potential for combating this aggressive malignancy.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Wang K, Xie CJ, Ding Z, et al. PDE5A+ cancer-associated fibroblasts enhance immune suppression in gastric cancer. Gut. 2025. PMID: 41115748. doi:10.1136/gutjnl-2025-335794

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。